Magnevist 469.01/78.63 Injection
Gadopentetic acid + Dimeglumine salt
Bayer Pharmaceuticals
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 2649.52 NPR |
Available as:
Indications
Magnevist 469.01/78.63 Injection is used for:
For contrast enhancement in direct magnetic resonance arthrography.
Adult Dose
The recommendations for the use of Gadopentetic acid + Dimeglumine salt 2 mmol/l apply to a field strength between 0.2 Tesla and 1.5 Tesla.
The lowest dose that provides sufficient enhancement for diagnostic purposes should be used.
In general, for all joints the administration of up to 20 ml (knee joint up to 50 ml) Gadopentetic acid + Dimeglumine salt 2 mmol/l is sufficient for good opacification and to answer all the relevant clinical questions.
A volume leading to a slight distension of the joint capsule should be injected.
Only so much contrast medium should be injected until discrete resistance is felt and/or the patient experiences a mild feeling of pressure.
Child Dose
Renal Dose
Administration
Contra Indications
Hypersensitivity to the active substance or to any of the excipients
Precautions
This medicinal product is for diagnostic use by intraarticular administration only.
Mild angioedema, conjunctivitis, coughing, pruritus, rhinitis, sneezing and urticaria, which can occur irrespective of the amount administered and the mode of administration, may be the first signs of incipient state of shock.
As with other contrast agents, delayed reactions may occur (hours later or up to several days).
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Gadopentetic acid + Dimeglumine salt :
The most frequently reported reactions were local injection site reactions, i.e. injection site pain and joint pressure sensations which are mainly related to the procedure itself.
Mechanism of Action
This is a paramagnetic contrast agent for magnetic resonance imaging. The contrast-enhancing effect is mediated by the di-N-methylglucamine salt of gadopentetic acid, dimeglumine - the gadolinium complex of pentetic acid (diethylene triamine pentaacetic acid = DTPA). When a suitable scanning sequence (e.g. T1-weighted spin-echo technique) is used in proton magnetic resonance imaging, the gadolinium ion-induced shortening of the spin-lattice relaxation time of excited atomic nuclei leads to an increase of the signal intensity and, hence, to an increase of the image contrast of certain tissues.
Note
Magnevist 469.01/78.63 Injection manufactured by Bayer Pharmaceuticals. Its generic name is Gadopentetic acid + Dimeglumine salt. Magnevist 469.01/78.63 is availble in Nepal.
Farmaco Nepal drug index information on Magnevist 469.01/78.63 Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.